The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-03 and is reviewed periodically as new material appears.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
In 1871, Thomas Lipton (1848–1931) of Glasgow, Scotland, used his small savings to open a shop; by the 1880s the business had grown to more than 200 stores. In 1929, the Lipton grocery retail business was one of the companies that merged with Home and Colonial Stores, Maypole Dairy Company, Vyes & Boroughs, Templetons and Galbraiths & Pearks to form a food group with more than 3,000 shops. The group traded in the High Street under various names, but was registered on the UK stock market as Allied Suppliers; Allied Stores was originally formed in 1929 to act as the group's purchasing arm. Lipton's became a supermarket chain focused on small towns. Allied was acquired by Argyll Foods in 1982; the supermarket business was rebranded as Presto during the 1980s.
==== Extensive development of "wasting-thirst" (265–1368) ==== The diagnosis and treatment of xiāo kě was expanded significantly through the Sui (581–618) and Tang (618–907) dynasties. Zeng Liyan (545–649) expounded on the diagnosis of modern-day diabetes mellitus through the presence of sugar in the urine (glycosuria). This characterization was echoed by other physicians in the centuries that followed. Notably, in Wàitái Mìyào (外臺秘要; "Medical Secrets of an Official") written in 752, Wang Tao (fl. 8th century AD) included a detailed case report of sweet urine and a summary of diabetology history before the Tang dynasty. Sun Simiao (581–682 AD) further developed approaches to treatment, prevention, regulation, nursing, and convalescence. The formulae for wasting-thirst grew from one in The Yellow Emperor's Classic of Internal Medicine, to nine in Zhang Zhongjing's works, to 73 in Sun Simiao's. The selection of herbs grew from one (Eupatorium fortunei), to dozens used by Zhang, to over one hundred used by Sun.
==== Increasing endogenous production ==== Regular exercise is known to increase DHEA production in the body. Calorie restriction has also been shown to increase DHEA in primates. Some theorize that the increase in endogenous DHEA brought about by calorie restriction is partially responsible for the longer life expectancy known to be associated with calorie restriction.
Sources: en.wikipedia.org
Outside Romania, public audiences in Western Europe initially projected generally idealistic notions of revolution on the country; the legacies of the French Revolution were fresh on people's minds in 1989 during its two-hundredth anniversary. However, as violence continued into 1990 and reports reached the West of mass casualties, this projected narrative shifted into a less sympathetic one characterized by disappointment in and suspicion of the revolution's direction.
Whatever may be the tendencies and inclinations, it must be emphasized that if America seeks to dictate to other powers their actions and policies, it can do so only by maintaining a preponderance of power manifested in an extension of political and economic control … But in the light of all recent history he who would consciously, deliberately elect that course is either unread, incapable of deductions from his reading or perverse. In self-contradiction, Peffer ended the article recommending for the postwar period a preponderance of power of offensive kind backed by total national effort: The United States will need "a larger permanent military establishment," alliances with other powers having common interests and an alliance with Great Britain that would be not only defensive but also "outright, unconditional offensive." It means full-scale power politics and to it "must be accommodated and sometimes subordinated everything else in the nation’s life." On 24 September 1946, Truman's Special Counsel Clark M. Clifford submitted a report "American Relations with the Soviet Union…" advocating a preponderant power:
Cabinets of Lower Saxony Since 1948, politics in the state have been dominated by the centre-right Christian Democratic Union (CDU) and the centre-left Social Democratic Party (SPD). Lower Saxony was one of the origins of the German environmentalist movement in reaction to the state government's support for underground nuclear waste disposal. This led to the formation of the German Green Party in 1980. Germany's multi-party system generally requires coalitions to be made because parties usually do not have outright majorities. The Minister-President heads the state government, acting as a head of state (even if the federated states have the status of a state do not establish the office of a head of state but merge the functions with the head of the executive branch) as well as the government leader. They are elected by the Landtag of Lower Saxony. The former Minister-President, Christian Wulff, led a coalition of his CDU with the Free Democratic Party between 2003 and 2010. In the 2008 election, the ruling CDU held on to its position as the leading party in the state, despite losing votes and seats. The CDU's coalition with the Free Democratic Party retained its majority although it was cut from 29 to 10. The election also saw the entry into the state parliament for the first time of the leftist The Left party. On 1 July 2010 David McAllister was elected Minister-President. After the state election on 20 January 2013, Stephan Weil of the Social Democrats was elected as the new Minister-President. He governed in coalition with the Greens.
The Journal of Biological Chemistry publishes research in any area of biochemistry or molecular biology in one online-only issue per week. Molecular & Cellular Proteomics is a monthly online only publication. Articles appearing in MCP "...describe the structural and functional properties of proteins and their expression, particularly with respect to the developmental time courses of the organism of which they are a part." The journal also publishes other content such as "HUPO views" (reports from the Human Proteome Organization), proceedings from HUPO meetings, and the proceedings of the International Symposium On Mass Spectrometry In The Life Sciences. The Journal of Lipid Research covers "...the science of lipids in health and disease. The Journal emphasizes lipid function and the biochemical and genetic regulation of lipid metabolism. In addition, JLR publishes manuscripts on patient-oriented and epidemiological research relating to altered lipid metabolism, including modification of dietary lipids." ASBMB Today is the society's monthly news magazine. It contains extensive coverage of awards, meetings, research highlights, job placement advertising and human interest articles. All ASBMB members receive a complimentary subscription to ASBMB Today. The online version of the magazine features daily publishing.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.